| P2093 | author name string | Xiang Hu | |
| | Ying Yuan | |
| | Yong Zhao | |
| | Zhen Cheng | |
| | Chao Jian | |
| | Ai-Xi Yu | |
| | Ai-Ming Yu | |
| | Yi-Zhou Li | |
| | Mei-Juan Tu | |
| | Peng-Cheng Li | |
| | Dai-Feng Li | |
| | Wan-Rong Yi | |
| P2860 | cites work | Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite | Q22122062 |
| | The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 | Q24617130 |
| | miR-34a repression of SIRT1 regulates apoptosis | Q24652720 |
| | Bioengineering of noncoding RNAs for research agents and therapeutics | Q26772092 |
| | microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment | Q26778918 |
| | Ki-67 acts as a biological surfactant to disperse mitotic chromosomes | Q28118669 |
| | The miR-34 family in cancer and apoptosis | Q28245865 |
| | Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34 | Q28285980 |
| | A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. | Q30539598 |
| | Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors | Q33437383 |
| | The Promise of MicroRNA Replacement Therapy | Q34134295 |
| | Targeting microRNAs in cancer: rationale, strategies and challenges | Q34141089 |
| | miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice | Q34146018 |
| | Caspase functions in cell death and disease | Q34336335 |
| | Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression. | Q50658268 |
| | Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. | Q52618071 |
| | RETRA exerts anticancer activity in Ewing's sarcoma cells independent of their TP53 status. | Q52956772 |
| | EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins | Q56459686 |
| | Ewing sarcoma | Q56609038 |
| | Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models | Q58589953 |
| | Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity | Q61810563 |
| | An Insight into the Roles of MicroRNAs and Exosomes in Sarcoma | Q64117030 |
| | Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression. | Q64900567 |
| | Common musculoskeletal tumors of childhood and adolescence | Q84072632 |
| | RNA therapy: Are we using the right molecules? | Q90309160 |
| | Risk stratification by somatic mutation burden in Ewing sarcoma | Q90850814 |
| | Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasis | Q91756783 |
| | Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs | Q92672846 |
| | A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications | Q35476690 |
| | Targeted therapies for advanced Ewing sarcoma family of tumors | Q35589492 |
| | Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth | Q36497652 |
| | MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy | Q36618667 |
| | MicroRNAs in Ewing Sarcoma | Q36722134 |
| | Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest | Q36928436 |
| | MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation | Q37276461 |
| | Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis | Q37753238 |
| | Posttranscriptional upregulation by microRNAs | Q37954590 |
| | MicroRNA Regulation of SIRT1. | Q38000257 |
| | MicroRNAs in the p53 network: micromanagement of tumour suppression | Q38035144 |
| | Therapy resistance mechanisms in Ewing's sarcoma family tumors | Q38182423 |
| | The p53/miR-34 axis in development and disease | Q38210767 |
| | Mir-34: a new weapon against cancer? | Q38253374 |
| | MicroRNA expression and its clinical implications in Ewing's sarcoma | Q38296481 |
| | MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor | Q38321646 |
| | Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma | Q38338166 |
| | Ewing Sarcoma: Current Management and Future Approaches Through Collaboration | Q38573422 |
| | MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation | Q38701992 |
| | MiRNA-194 activates the Wnt/β-catenin signaling pathway in gastric cancer by targeting the negative Wnt regulator, SUFU. | Q38733212 |
| | MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway | Q39024985 |
| | MicroRNA therapeutics: towards a new era for the management of cancer and other diseases | Q39139786 |
| | microRNAs as cancer therapeutics: A step closer to clinical application | Q39244582 |
| | miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 |
| | miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells | Q39917469 |
| | Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest | Q39992760 |
| | Targeting the p53 Pathway in Ewing Sarcoma. | Q41303735 |
| | The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p. | Q47116057 |
| | Advances in sarcoma gene mutations and therapeutic targets. | Q47347148 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 222 | |
| P577 | publication date | 2020-02-25 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | The Optimal Outcome of Suppressing Ewing Sarcoma Growth in vivo With Biocompatible Bioengineered miR-34a-5p Prodrug | |
| P478 | volume | 10 | |